ClinConnect ClinConnect Logo
Search / Trial NCT01845272

Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate

Launched by HK INNO.N CORPORATION · Apr 30, 2013

Trial Information

Current as of May 25, 2025

Unknown status

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Male volunteers in the age between 20 and 55 years old(inclusive)
  • Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)
  • Available for the entire study period
  • Understand the requirements of the study and voluntarily consent to participate in the study
  • Exclusion Criteria:
  • Subjects with a history of gastrointestinal diseases which might significantly change ADME of medicines
  • Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood pressure outside the range of 60 to 1000 mmHg for male subjects. when screening period
  • Subject with symptoms of acute disease within 14days prior to study medication dosing
  • Subjects with a history of clinically significant allergies
  • Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT \>1.5 times to normal range or total bilirubin \> 1.5times to normal range)
  • History of drug abuse
  • History of caffeine, alcohol, smoking abuse
  • caffeine(coffee,tea,coke) or grapefruit juice \> 4cups/day
  • smoking \> 20 cigarettes/day
  • alcohol \> 140g/week
  • Positive test results for HBs Ab, HCV Ab, Syphilis regain test
  • Participation in any clinical investigation within 30days prior to study medication dosing
  • Subjects with whole blood donation within 60days, component blood donation within 30days and blood transfusion within 30days prior to study medication dosing
  • Subjects considered as unsuitable based on medical judgement by investigators

About Hk Inno.N Corporation

hk inno.n corporation is a pioneering biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs. With a strong focus on research and development, the company leverages cutting-edge technologies and scientific expertise to create novel treatment solutions across various therapeutic areas. Committed to high standards of clinical excellence and patient safety, hk inno.n collaborates with leading research institutions and healthcare professionals to drive the progress of its clinical trials, aiming to enhance patient outcomes and contribute to the global healthcare landscape.

Locations

Patients applied

0 patients applied

Trial Officials

Jae-wook Ko, MD, PhD

Principal Investigator

Samsung Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials